Interestingly, in NSCLC, anti-PD-1 therapy (pembrolizumab) demonstrated superiority over chemotherapy in patients with ≥50% or <1% tumor PD-L1 scores, but this benefit was absent in patients with 1–49% tumor PD-L1 scores (200). This evidence concerns the gene PDCD1 and neoplasm.